Revvity Future Growth

Future criteria checks 3/6

Revvity is forecast to grow earnings and revenue by 23.9% and 5.4% per annum respectively. EPS is expected to grow by 24.4% per annum. Return on equity is forecast to be 8.5% in 3 years.

Key information

23.9%

Earnings growth rate

24.4%

EPS growth rate

Life Sciences earnings growth	16.7%
Revenue growth rate	5.4%
Future return on equity	8.5%
Analyst coverage	Good
Last updated	22 Apr 2024

Recent future growth updates

Recent updates

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Jan 04

Revvity: More Than A Name Change Is Needed For PerkinElmer

Dec 29

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Dec 20

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Oct 07

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Oct 04

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Sep 22

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Aug 17

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Jul 18

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Jul 03

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Jun 17

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

May 16

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

Mar 28

When Should You Buy PerkinElmer, Inc. (NYSE:PKI)?

Mar 13

PerkinElmer Q4 2022 Earnings Preview

Feb 13

A Look At The Intrinsic Value Of PerkinElmer, Inc. (NYSE:PKI)

Feb 10

PerkinElmer: Capital Budgeting A Key Factor To The Investment Debate

Jan 31

Danaher earnings weigh on other life sciences tools, services companies

Jan 24

PerkinElmer says Q4 results will meet or exceed prior guidance

Jan 09

PerkinElmer (NYSE:PKI) Has A Pretty Healthy Balance Sheet

Dec 27

Is It Time To Consider Buying PerkinElmer, Inc. (NYSE:PKI)?

Dec 12

PerkinElmer receives FDA approval for EONIS assay for spinal muscular atrophy in newborns

Nov 14

PerkinElmer reports mixed Q3 earnings, initiates Q4 and updates FY22 pro forma guidance

Nov 08

PerkinElmer, Inc.'s (NYSE:PKI) Intrinsic Value Is Potentially 48% Above Its Share Price

Oct 28

PerkinElmer declares $0.07 dividend

Oct 27

PerkinElmer expects Q3 earnings to exceed prior outlook

Oct 17

Earnings and Revenue Growth Forecasts

NYSE:RVTY - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	3,238	388	713	801	6
12/31/2025	3,011	339	650	732	13
12/31/2024	2,813	276	453	532	14
12/31/2023	2,751	180	10	91	N/A
10/1/2023	2,796	213	-50	34	N/A
7/2/2023	2,837	250	153	227	N/A
4/2/2023	3,024	353	380	460	N/A
1/1/2023	3,312	513	594	680	N/A
10/2/2022	3,599	599	790	876	N/A
7/3/2022	3,748	637	932	1,030	N/A
4/3/2022	3,483	694	1,122	1,220	N/A
1/2/2022	3,828	889	1,325	1,411	N/A
10/3/2021	4,155	1,086	1,478	1,557	N/A
7/4/2021	4,257	1,155	1,380	1,455	N/A
4/4/2021	4,438	1,074	1,234	1,306	N/A
1/3/2021	2,663	631	829	892	N/A
10/4/2020	3,234	412	545	625	N/A
7/5/2020	2,977	294	444	521	N/A
4/5/2020	2,887	226	352	429	N/A
12/29/2019	2,884	228	282	363	N/A
9/29/2019	2,835	235	217	308	N/A
6/30/2019	2,802	251	199	294	N/A
3/31/2019	2,783	247	225	320	N/A
12/30/2018	2,778	237	218	311	N/A
9/30/2018	2,663	128	203	280	N/A
7/1/2018	2,543	149	178	245	N/A
4/1/2018	2,387	147	164	220	N/A
12/31/2017	2,257	157	249	288	N/A
10/1/2017	2,182	258	N/A	309	N/A
7/2/2017	2,142	215	N/A	324	N/A
4/2/2017	2,132	210	N/A	372	N/A
1/1/2017	2,116	216	N/A	351	N/A
10/2/2016	1,999	198	N/A	327	N/A
7/3/2016	2,048	199	N/A	314	N/A
4/3/2016	2,076	190	N/A	281	N/A
1/3/2016	2,105	189	N/A	287	N/A
10/4/2015	2,263	176	N/A	258	N/A
6/28/2015	2,241	164	N/A	261	N/A
3/29/2015	2,234	167	N/A	252	N/A
12/28/2014	2,070	130	N/A	282	N/A
9/28/2014	2,221	203	N/A	257	N/A
6/29/2014	2,201	201	N/A	242	N/A
3/30/2014	2,185	176	N/A	215	N/A
12/29/2013	2,158	174	N/A	159	N/A
9/29/2013	2,139	85	N/A	126	N/A
6/30/2013	2,126	73	N/A	99	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RVTY's forecast earnings growth (23.9% per year) is above the savings rate (2.3%).

Earnings vs Market: RVTY's earnings (23.9% per year) are forecast to grow faster than the US market (14.7% per year).

High Growth Earnings: RVTY's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: RVTY's revenue (5.4% per year) is forecast to grow slower than the US market (8.1% per year).

High Growth Revenue: RVTY's revenue (5.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RVTY's Return on Equity is forecast to be low in 3 years time (8.5%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Revvity Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Price target increased by 8.9% to US$122

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Consensus EPS estimates fall by 15%

Price target decreased by 22% to US$107

Recent updates

Revvity Unveils A New Era of Automated Tuberculosis Testing

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity: Enter Now As Reorganization Takes Shape

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

We Think Revvity (NYSE:RVTY) Can Stay On Top Of Its Debt

Investors Can Find Comfort In Revvity's (NYSE:RVTY) Earnings Quality

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

CEO, President & Director notifies of intention to sell stock

New minor risk - Earnings quality

Price target increased by 8.9% to US$122

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Full year 2023 earnings: EPS exceeds analyst expectations

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Dividend of US$0.07 announced

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now?

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Revvity: More Than A Name Change Is Needed For PerkinElmer

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Consensus EPS estimates fall by 15%

Price target decreased by 22% to US$107

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued after recent price drop

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Upcoming dividend of US$0.07 per share at 0.2% yield

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Now 22% undervalued after recent price drop

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

Consensus EPS estimates increase by 42%, revenue downgraded

Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.

First quarter 2023 earnings: EPS exceeds analyst expectations

Insider notifies of intention to sell stock

Upcoming dividend of US$0.07 per share at 0.2% yield

Insufficient new directors

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

Insider notifies of intention to sell stock

When Should You Buy PerkinElmer, Inc. (NYSE:PKI)?

Consensus EPS estimates fall by 15%

PerkinElmer, Inc. Provides Earnings Guidance for the Full Year of 2023

Full year 2022 earnings: Revenues and EPS in line with analyst expectations